Molecular Partners

Molecular Partners

Biotechnology
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

$136.4M

Market Cap • 10/16/2026

2004

(22 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Switzerland

Switzerland

Country

Valuation

P/B

1,9

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

1,9

EPS

—

Market Cap

Market Cap

136,4M

EV

56,1M

EV/Revenue

0

EV/EBITDA

-0,9

EV/EBIT

-0,9

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,1%

Total Yield

-0,1%

Payout

0%

Retained Earnings

-414,4M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

9,4%

Capex/OCF

-0,4%

SBC/OCF

—

% PPE

5,6%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-100%

CAGR Op. Income 5Y

-3,5%

CAGR Net Income 5Y

-4,1%

CAGR EPS 5Y

-9,3%

CAGR OCF 5Y

-0,7%

Leverage

N.D./EBITDA

1,3

Debt/Equity

0%

Current Ratio

7,3

Quick Ratio

7,1

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium